High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer

  • Yumi Endo
  • Tatsuya Toyama
  • Satoru Takahashi
  • Hiroshi Sugiura
  • Nobuyasu Yoshimoto
  • Mai Iwasa
  • Shunzo Kobayashi
  • Yoshitaka Fujii
  • Hiroko Yamashita
Original Article

Abstract

Background

Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, many breast cancer patients with tumors expressing ER are unresponsive to aromatase inhibitors, and all patients with advanced disease eventually develop resistance to the therapy.

Methods

Twenty-one postmenopausal women with Stage II to IV breast cancer were treated with aromatase inhibitors as first-line endocrine therapy without surgery. Expression levels of ER, progesterone receptor, HER2 and Ki67 were examined by immunohistochemistry, and correlations between response and duration of the therapy and these levels were analyzed.

Results

Patients whose tumors contained two thirds or more ER-positive cells effectively responded to aromatase inhibitors (P = 0.006) and displayed longer time to progression during first-line endocrine therapy (P = 0.003) and longer time to endocrine therapy failure (P = 0.02). Patients whose tumors showed less than 15% Ki67 labeling index also displayed longer time to progression (P = 0.003).

Conclusion

High ER expression and low Ki67 expression were associated with improved time to progression with aromatase inhibitors as first-line endocrine therapy. Our findings will be helpful when endocrine therapy is planned in either early stage or advanced breast cancer.

Keywords

Breast cancer Estrogen receptor Ki67 Endocrine therapy Aromatase inhibitor 

Abbreviations

ER

Estrogen receptor

PgR

Progesterone receptor

HER2

Human epidermal growth factor receptor type 2

CR

Complete response

PR

Partial response

SD

Stable disease

IHC

Immunohistochemistry

Ki67 LI

Ki67 labeling index

Notes

Conflict of interest

All authors have no conflict of interest to disclose.

References

  1. 1.
    Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15:278–290PubMedCrossRefGoogle Scholar
  2. 2.
    Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796PubMedCrossRefGoogle Scholar
  3. 3.
    Cardoso F, Senkus-Konefka E, Fallowfield L et al (2010) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):15–19CrossRefGoogle Scholar
  4. 4.
    Dowsett M, Ebbs SR, Dixon JM et al (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 23:2477–2492PubMedCrossRefGoogle Scholar
  5. 5.
    Dowsett M, Smith IE, Ebbs SR et al (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170PubMedCrossRefGoogle Scholar
  6. 6.
    Yamashita H, Takahashi S, Ito Y et al (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100:2028–2033PubMedCrossRefGoogle Scholar
  7. 7.
    Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816PubMedGoogle Scholar
  8. 8.
    Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065PubMedCrossRefGoogle Scholar
  9. 9.
    Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28PubMedCrossRefGoogle Scholar
  10. 10.
    (2005) General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 12 Supplement 2005:S8Google Scholar
  11. 11.
    Yamashita H, Nishio M, Toyama T et al (2008) Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15:755–763PubMedCrossRefGoogle Scholar
  12. 12.
    Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMedGoogle Scholar
  13. 13.
    Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRefGoogle Scholar
  14. 14.
    Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329PubMedCrossRefGoogle Scholar
  15. 15.
    Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183PubMedCrossRefGoogle Scholar
  16. 16.
    Rosa FE, Caldeira JR, Felipes J et al (2008) Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 39:720–730PubMedCrossRefGoogle Scholar
  17. 17.
    Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25:3846–3852PubMedCrossRefGoogle Scholar
  18. 18.
    Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575PubMedCrossRefGoogle Scholar
  19. 19.
    Kai K, Nishimura R, Arima N et al (2006) p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 11:426–433PubMedCrossRefGoogle Scholar
  20. 20.
    Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176PubMedCrossRefGoogle Scholar
  21. 21.
    Penault-Llorca F, Andre F, Sagan C et al (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2809–2815PubMedCrossRefGoogle Scholar
  22. 22.
    Viale G, Regan MM, Mastropasqua MG et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207–212PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2011

Authors and Affiliations

  • Yumi Endo
    • 1
  • Tatsuya Toyama
    • 1
  • Satoru Takahashi
    • 2
  • Hiroshi Sugiura
    • 1
  • Nobuyasu Yoshimoto
    • 1
  • Mai Iwasa
    • 1
  • Shunzo Kobayashi
    • 1
  • Yoshitaka Fujii
    • 1
  • Hiroko Yamashita
    • 1
  1. 1.Oncology, Immunology and SurgeryNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Experimental Pathology and Tumor BiologyNagoya City University Graduate School of Medical SciencesNagoyaJapan

Personalised recommendations